Financial Daily from THE HINDU group of publications
Saturday, May 22, 2004

Cross Currency

Group Sites

Corporate - Alliances & Joint Ventures

Pfizer arm in pact with Siro Clinpharm

Our Bureau

Mumbai , May 21

PFIZER Global Research and Development, through its affiliate in India, has entered into a partnership with Siro Clinpharm, a clinical research organisation.

The agreement covers the provision of clinical data management and biometrics services, an official communiqué said. Looking to leverage the cost advantage that India offers, the partnership would also allow Pfizer to tap into the domestic scientific pool.

Pfizer India Biometrics Division has been providing data capture, data management, statistics and programming services for its parent - Pfizer Inc's Phase I, II and III global trials for over six years. It is well known for its prompt and quality delivery, with error rates that are among the lowest worldwide.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Baxter's new blood collection system

IOC finalises deal with RIL for petro goods offtake
Wander to tap capital market
Trading licence of Tata Power cleared
Voltas to exit venture with France's Sermo Montaigu
Devaki Hospital sees management change
Tata Power: Prepayment of foreign currency loans hits profits
The dilemma of the L&T shareholder
HC okays Tata Chem, Hind Lever Chem merger
SRF board nod on Kashipur plant buy
Sundram Fasteners inaugurates China plant
Banswara Syntex sets up trouser factory in Daman
Pfizer arm in pact with Siro Clinpharm
Punjab Tractors bullish on exports; eyes US market
Kinetic pins hopes on `honest pricing'
Cetex Petro to focus on fine chemicals biz
Kinetic targets 20 pc growth in topline

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line